ABC AUSTRALIA | Over the past 12 years, two scientists have been developing a new antibiotic that recently began phase 1 clinical trials in the US. This promising new drug, with the uninspiring name QPX9003, has placed the pair on the cusp of achieving something that hasn’t been done for decades.